These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 29892519)

  • 21. Histomorphometric and microarchitectural analysis of bone in metastatic breast cancer patients.
    Beltran-Bless A; Murshed M; Zakikhani M; Kuchuk I; Bouganim N; Robertson S; Kekre N; Vandermeer L; Li J; Addison CL; Rauch F; Clemons M; Kremer R
    Bone Rep; 2021 Dec; 15():101145. PubMed ID: 34841014
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Examination of burden of skeletal-related events in patients naive to denosumab and intravenous bisphosphonate therapy in bone metastases from solid tumors population.
    Bhowmik D; Song X; Intorcia M; Gray S; Shi N
    Curr Med Res Opin; 2019 Mar; 35(3):513-523. PubMed ID: 30286662
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bisphosphonates for breast cancer.
    Pavlakis N; Schmidt R; Stockler M
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid.
    Cleeland CS; Body JJ; Stopeck A; von Moos R; Fallowfield L; Mathias SD; Patrick DL; Clemons M; Tonkin K; Masuda N; Lipton A; de Boer R; Salvagni S; Oliveira CT; Qian Y; Jiang Q; Dansey R; Braun A; Chung K
    Cancer; 2013 Feb; 119(4):832-8. PubMed ID: 22951813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment Patterns, Safety, and Patient Reported Outcomes among Adult Women with Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer with or without, or with Unknown,
    Lux MP; Lewis K; Rider A; Niyazov A
    Breast Care (Basel); 2022 Oct; 17(5):460-469. PubMed ID: 36684399
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Are bone targeted agents still useful in times of immunotherapy? The SAKK 80/19 BTA pilot study.
    Mark M; Mora AR; Winder T; Stathis A; Jakob A; Müller G; Hayoz S; Reimann P; Petrausch U; von Moos R;
    Bone Rep; 2024 Sep; 22():101794. PubMed ID: 39139592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Osteonecrosis of the jaw among patients with cancer treated with denosumab or zoledronic acid: Results of a regulator-mandated cohort postauthorization safety study in Denmark, Norway, and Sweden.
    Ehrenstein V; Heide-Jørgensen U; Schiødt M; Akre O; Herlofson BB; Hansen S; Larsson Wexell C; Nørholt SE; Tretli S; Kjellman A; Glennane A; Lowe KA; Sørensen HT
    Cancer; 2021 Nov; 127(21):4050-4058. PubMed ID: 34310704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS).
    Wirth M; Tammela T; Cicalese V; Gomez Veiga F; Delaere K; Miller K; Tubaro A; Schulze M; Debruyne F; Huland H; Patel A; Lecouvet F; Caris C; Witjes W
    Eur Urol; 2015 Mar; 67(3):482-91. PubMed ID: 24630685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors.
    Manglaviti S; Bini M; Apollonio G; Zecca E; Galli G; Sangaletti S; Labianca A; Sottotetti E; Brambilla M; Occhipinti M; Proto C; Prelaj A; Signorelli D; De Toma A; Viscardi G; Beninato T; Mazzeo L; Bottiglieri A; Leporati R; Fotia G; Ganzinelli M; Portararo P; Garassino MC; de Braud FGM; Lo Russo G; Torri V; Ferrara R
    Lung Cancer; 2023 Dec; 186():107417. PubMed ID: 37918061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
    Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
    J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A 'hypothesis-generator' study from clinical practice.
    Cortellini A; Cocciolone V; Irelli A; Pavese F; Sidoni T; Parisi A; Lanfiuti Baldi P; Venditti O; D'Orazio C; Bonfili P; Franzese P; Zugaro L; Verna L; Porzio G; Santini D; Cannita K; Ficorella C
    Oncol Lett; 2018 Dec; 16(6):7195-7203. PubMed ID: 30546457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bisphosphonates for breast cancer.
    Pavlakis N; Stockler M
    Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid.
    Martin M; Bell R; Bourgeois H; Brufsky A; Diel I; Eniu A; Fallowfield L; Fujiwara Y; Jassem J; Paterson AH; Ritchie D; Steger GG; Stopeck A; Vogel C; Fan M; Jiang Q; Chung K; Dansey R; Braun A
    Clin Cancer Res; 2012 Sep; 18(17):4841-9. PubMed ID: 22893628
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.
    Himelstein AL; Foster JC; Khatcheressian JL; Roberts JD; Seisler DK; Novotny PJ; Qin R; Go RS; Grubbs SS; O'Connor T; Velasco MR; Weckstein D; O'Mara A; Loprinzi CL; Shapiro CL
    JAMA; 2017 Jan; 317(1):48-58. PubMed ID: 28030702
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-World Evaluation of Primary Versus Secondary Prevention of Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer.
    Phillips WJ; Saad F; Leigh J; Jooya A; Webber C; Morgan S; MacRae R; Bourque JM; Tanuseputro P; Ong M
    Oncologist; 2024 Mar; ():. PubMed ID: 38527096
    [TBL] [Abstract][Full Text] [Related]  

  • 36. N-Telopeptide of Type I Collagen Long-Term Dynamics in Breast Cancer Patients With Bone Metastases: Clinical Outcomes and Influence of Extraskeletal Metastases.
    Ferreira AR; Alho I; Shan N; Matias M; Faria M; Casimiro S; Leitzel K; Ali S; Lipton A; Costa L
    Oncologist; 2016 Dec; 21(12):1418-1426. PubMed ID: 27534575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2-negative advanced breast cancer from the United States, Europe, and Israel.
    Mahtani R; Niyazov A; Arondekar B; Lewis K; Rider A; Massey L; Lux MP
    BMC Cancer; 2022 Dec; 22(1):1343. PubMed ID: 36550413
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Denosumab treatment in the management of patients with advanced prostate cancer: clinical evidence and experience.
    Hegemann M; Bedke J; Stenzl A; Todenhöfer T
    Ther Adv Urol; 2017; 9(3-4):81-88. PubMed ID: 28392837
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted treatments of bone metastases in patients with lung cancer.
    Hirsh V
    Front Oncol; 2014; 4():146. PubMed ID: 24982847
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer.
    Delea T; Langer C; McKiernan J; Liss M; Edelsberg J; Brandman J; Sung J; Raut M; Oster G
    Oncology; 2004; 67(5-6):390-6. PubMed ID: 15713995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.